|
Synonyms: CAM-3001 | KPL-301
Compound class:
Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| A phase 2 clinical trial (NCT01712399) of mavrilimumab in adult rheumatoid arthritis (RA) patients has been completed (May 2017). In these patients mavrilimumab produced a rapid and prolonged reduction in interleukin-6 production which is indicative of suppression of tissue inflammation. Further development in RA has been discontinued, however Kiniksa Pharmaceuticals are actively evaluating mavrilimumab (which they have re-coded as KPL-301) in a Phase 2 trial in patients with giant cell arteritis (GCA) [3]. |
| Mechanism Of Action and Pharmacodynamic Effects |
| GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Antibody binding results in decreased GM-CSF-induced activation of the GM-CSFRα. This helps to reduce neutrophil derived TNFα, and induces clinical remission and reduce flares in patients with RA [4]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01712399 | A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis | Phase 2 Interventional | MedImmune LLC | ||
| NCT03827018 | KPL-301 for Subjects With Giant Cell Arteritis | Phase 2 Interventional | Kiniksa Pharmaceuticals, Ltd. | ||
